Piotr Adrian Klimiuk

List of Publications by Year
in descending order

Version: 2024-02-01

44 papers	2,122 citations	279798 23 h-index	315739 38 g-index
44 all docs	44 docs citations	44 times ranked	2602 citing authors

#	Article	IF	Citations
1	Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis. Rheumatology, 2022, 61, 1385-1395.	1.9	10
2	Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. Arthritis Research and Therapy, 2021, 23, 51.	3.5	18
3	Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext). Expert Opinion on Biological Therapy, 2019, 19, 1097-1105.	3.1	21
4	Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212245.	0.9	88
5	Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a Phase II open-label clinical study (VOLTAIRE^{Â®}-RL). Expert Opinion on Drug Delivery, 2018, 15, 545-548.	5.0	8
6	FRI0189â€…Similar efficacy and safety of biosimilar candidate BI 695501 and adalimumab originator reference product in patients with moderate to severe active rheumatoid arthritis: 24 week results from a phase III clinical study (voltaireÂ®-ra). , 2017, , .		1
7	Evaluation of foot static disturbances in patients with rheumatic diseases. Reumatologia, 2017, 55, 73-78.	1.1	5
8	AB1095-HPRâ€…Evaluation of The Static Foot Function in Patients with Reduced Mobility in The Course of Rheumatic Diseases. Annals of the Rheumatic Diseases, 2016, 75, 1306.2-1306.	0.9	0
9	Changes of glycosylation of IgG in rheumatoid arthritis patients treated with methotrexate. Advances in Medical Sciences, 2016, 61, 193-197.	2.1	41
10	AB0675â€…Correlation Between Microvascular Abnormalities in Videocapillaroscopy and Angiogenesis Modulators in Patients with Raynaud's Phenomenon Before and After Multiwave Locked System (MLS) Laser Therapy. Annals of the Rheumatic Diseases, 2015, 74, 1124.1-1124.	0.9	0
11	Regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers. Rheumatology International, 2015, 35, 749-755.	3.0	12
12	The influence of Multiwave Locked System (MLS) laser therapy on clinical features, microcirculatory abnormalities and selected modulators of angiogenesis in patients with Raynaudâ€™s phenomenon. Clinical Rheumatology, 2015, 34, 489-496.	2.2	13
13	Association between type 1 diabetes and periodontal health. Advances in Medical Sciences, 2014, 59, 126-131.	2.1	39
14	Intraoperative bleeding during endoscopic sinus surgery and microvascular density of the nasal mucosa. Advances in Medical Sciences, 2014, 59, 132-135.	2.1	9
15	AB0121â€…Changes of Glycosylation of Immunoglobulin G in Rheumatoid Arthritis Patients Treated with Methotrexate. Annals of the Rheumatic Diseases, 2014, 73, 844.1-844.	0.9	0
16	THU0557â€…Nailfold Videocapillaroscopic Abnormalities and Selected Angiogenesis Modulators in Patients with Raynaud's Phenomenon after Multiwave Locked System (MLS) Laser Therapy. Annals of the Rheumatic Diseases, 2014, 73, 375.2-375.	0.9	0
17	AB0447â€…Regulation of Serum Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases-1 following Rituximab Therapy in Patients with Rheumatoid Arthritis Refractory to Anti-Tumor Necrosis Factor Blockers. Annals of the Rheumatic Diseases, 2014, 73, 956.1-956.	0.9	0
18	Endothelial dysfunction in Graves' disease. Advances in Medical Sciences, 2013, 58, 31-37.	2.1	10

#	Article	IF	Citations
19	Assessment of the efficacy of laser biostimulation and low-frequency pulsed magnetic field in the treatment of microvascular abnormalities in patients with Raynaudâ€™s phenomenon. Reumatologia, 2012, 5, 410-415.	1.1	1
20	Serum chemokines in patients with rheumatoid arthritis treated with etanercept. Rheumatology International, 2011, 31, 457-461.	3.0	22
21	Analysis of correlations between selected endothelial cell activation markers, disease activity, and nailfold capillaroscopy microvascular changes in systemic lupus erythematosus patients. Clinical Rheumatology, 2010, 29, 175-180.	2.2	29
22	Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity. Scandinavian Journal of Rheumatology, 2009, 38, 38-45.	1.1	35
23	The changes in serum chemokines following leflunomide therapy in patients with rheumatoid arthritis. Clinical Rheumatology, 2009, 28, 17-21.	2.2	8
24	Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 Scandinavian Journal of Rheumatology, 2009, 38, 439-444.	1.1	22
25	Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus. Journal of Rheumatology, 2008, 35, 1307-13.	2.0	21
26	Soluble cell adhesion molecules (sICAMâ€1, sVCAMâ€1, and sEâ€selectin) in patients with early rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2007, 36, 345-350.	1.1	44
27	Vascular endothelial growth factor in systemic lupus erythematosus: relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalities. Archivum Immunologiae Et Therapiae Experimentalis, 2007, 55, 179-185.	2.3	50
28	The changes in monosaccharide composition of immunoglobulin G in the course of rheumatoid arthritis. Clinical Rheumatology, 2007, 26, 685-690.	2.2	42
29	A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis. Clinical Rheumatology, 2006, 25, 314-319.	2.2	41
30	Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis. Journal of Rheumatology, 2006, 33, 1523-9.	2.0	51
31	Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clinical Rheumatology, 2005, 24, 111-116.	2.2	105
32	Histological patterns of synovitis and serum chemokines in patients with rheumatoid arthritis. Journal of Rheumatology, 2005, 32, 1666-72.	2.0	39
33	Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. Journal of Rheumatology, 2004, 31, 238-42.	2.0	45
34	Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. Archivum Immunologiae Et Therapiae Experimentalis, 2004, 52, 36-42.	2.3	18
35	Circulating tumour necrosis factor alpha and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis. Annals of the Rheumatic Diseases, 2003, 62, 472-475.	0.9	56
36	Synoviocyte-Mediated Expansion of Inflammatory T Cells in Rheumatoid Synovitis Is Dependent on CD47-Thrombospondin 1 Interaction. Journal of Immunology, 2003, 171, 1732-1740.	0.8	63

#	Article	IF	Citations
37	Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Annals of the Rheumatic Diseases, 2002, 61, 804-809.	0.9	117
38	Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis. Rheumatology, 2002, 41, 78-87.	1.9	56
39	T Cell Activation in Rheumatoid Synovium Is B Cell Dependent. Journal of Immunology, 2001, 167, 4710-4718.	0.8	443
40	Central Role of Thrombospondin-1 in the Activation and Clonal Expansion of Inflammatory T Cells. Journal of Immunology, 2000, 164, 2947-2954.	0.8	109
41	Production of Cytokines and Metalloproteinases in Rheumatoid Synovitis Is T Cell Dependent. Clinical Immunology, 1999, 90, 65-78.	3.2	107
42	Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis. Journal of Clinical Investigation, 1999, 103, 1007-1013.	8.2	187
43	Heterogeneity of rheumatoid arthritis: from phenotypes to genotypes. Seminars in Immunopathology, 1998, 20, 5-22.	4.0	106
44	Circulating intercellular adhesion molecule 1 in rheumatoid arthritis â€" Relationship to systemic vasculitis and microvascular injury in nailfold capillary microscopy. Clinical Rheumatology, 1996, 15, 367-373.	2.2	30